Dennis E. Mayock, MD

"My goal is to provide the best evidenced-based medical care to newborns. When evidence is not available on which to base clincal decisions, I feel obligated to pursue such answers through clinical research projects. Generation of new evidence remains my primary focus."

Dr. Mayock's basic research interests include evaluation of the effects of fetal and neonatal drug (alcohol, morphine) exposure on fetal, neonatal and adult cerebrovascular function. Dr. Mayock's clinical research interests include evaluation of therapies that potentially may improve the outcomes in infants at risk for neurodevelopmental impairment, and treatments that may alter the likehood of developing Bronchopulmonary Dysplasia such as inhaled nitric oxide and late surfactant treatments.

In collaboration with Drs. Juul and Gleason, he is evaluating whether high dose erythropoietin treatment has neuroprotective effects in preterm and term infants. In collaboration with Dr. Meghan Delaney, he is exploring different methods of protecting infants from transfusion related CMV disease.

Seattle Children’s provides healthcare without regard to race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry) or disability. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.